Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 592 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BMD Clear all
Active, not recruiting Not applicable Interventional

VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)

NCT04573946
View directory record Official record
Conditions
Bone Density, Bone Health, Fractures
Interventions
Vitamin D3 placebo, Fish oil placebo, Omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Romosozumab in Women With Chronic SCI

NCT04708886
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis
Interventions
Romosozumab, Alendronate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

Dual Energy Cone-Beam Computed Tomography (DE-CBCT) Assessment of Jaw Bone Density

NCT04686084
View directory record Official record
Conditions
Dental Diseases
Interventions
Dual-energy computed tomography scan
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

NCT04779216
View directory record Official record
Conditions
Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
Interventions
Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg
Drug
Lead sponsor
Karen Klahr Miller, MD
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

NCT01128855
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
3 mg/kg GSK2402968, 6 mg/kg GSK2402968, 9 mg/kg GSK2402968, 12 mg/kg GSK2402968, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of DHEA and Exercise in the Elderly

NCT00205686
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DHEA, exercise
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years to 78 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2006 · Synced Jun 11, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

NCT04232657
View directory record Official record
Conditions
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Interventions
Romosozumab, Denosumab, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 11, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

NCT03960554
View directory record Official record
Conditions
Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions
Denosumab Inj 60 mg/ml, Placebo
Drug · Other
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jun 11, 2026, 4:14 AM EDT
Terminated Phase 4 Interventional

An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

NCT04708314
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
Drug
Lead sponsor
Rare Disease Research, LLC
Other
Eligibility
7 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 11, 2026, 4:14 AM EDT
Withdrawn Phase 2 Interventional

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

NCT02230917
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Sotatercept, Placebo
Drug
Lead sponsor
Rebecca Silbermann
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

Texture Analysis for Postmenopausal Osteoporosis

NCT00145977
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Alendronate, Calcium Citrate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jun 11, 2026, 4:14 AM EDT
Completed No phase listed Observational

The Influence of Local Bone Status on Complications After Surgical Treatment of Distal Radius Fractures

NCT01144208
View directory record Official record
Conditions
Distal Radius Fractures, Poor Bone Quality, Treatment Complications
Interventions
Not listed
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
50 Years to 90 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Jun 11, 2026, 4:14 AM EDT
Not listed No phase listed Observational

Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism

NCT03052075
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Retrospective Data Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03703882
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

NCT00048074
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Irvine, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jun 11, 2026, 4:14 AM EDT
Recruiting No phase listed Observational

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

NCT05683379
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AAV8 DetectCDx
Diagnostic Test
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
0 Years to 25 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 11, 2026, 4:14 AM EDT
Active, not recruiting Phase 3 Interventional

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PTH And Calcium Responses to Exercise (PACE) in Older Adults

NCT02468817
View directory record Official record
Conditions
Osteoporosis
Interventions
Treadmill Exercise, Magnitude of Ca loss during Exercise at 26 degrees Celcius
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

NCT06250283
View directory record Official record
Conditions
Low Bone Mass
Interventions
Resveratrol, Placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Self Regulated Physical Activity and Bone Growth Enhancement in Premature Infants

NCT03884322
View directory record Official record
Conditions
Prematurity, VLBW - Very Low Birth Weight Infant
Interventions
Prepod, Joint compression exercises
Other · Procedure
Lead sponsor
Asante Health System
Other
Eligibility
32 Weeks to 36 Weeks
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

NCT03292146
View directory record Official record
Conditions
Bone Density, Bone Loss, Anorexia Nervosa, Eating Disorder, Atypical Anorexia Nervosa
Interventions
Denosumab 60 MG [Prolia], Placebo Injection, Alendronate 70Mg Tab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Patient Activation After DXA Result Notification

NCT01507662
View directory record Official record
Conditions
Osteoporosis, Bone Diseases, Metabolic
Interventions
Bone Mineral Density Result Letter and Bone Health Brochure
Behavioral
Lead sponsor
Fredric D Wolinsky
Other
Eligibility
50 Years and older
Enrollment
7,749 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jun 11, 2026, 4:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

NCT03039686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
RO7239361, Placebo for RO7239361
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Years to 11 Years · Male only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jun 11, 2026, 4:14 AM EDT